Colgate-Palmolive (NYSE:CL) Given New $107.00 Price Target at Deutsche Bank Aktiengesellschaft

Colgate-Palmolive (NYSE:CL) had its target price upped by investment analysts at Deutsche Bank Aktiengesellschaft from $104.00 to $107.00 in a report released on Monday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. Deutsche Bank Aktiengesellschaft’s target price indicates a potential upside of 6.61% from the stock’s current price.

A number of other research firms have also recently issued reports on CL. Royal Bank of Canada boosted their price objective on Colgate-Palmolive from $88.00 to $95.00 and gave the company a “sector perform” rating in a research report on Monday, April 29th. Stifel Nicolaus increased their price objective on shares of Colgate-Palmolive from $95.00 to $105.00 and gave the company a “buy” rating in a research note on Monday, July 22nd. HSBC reiterated a “hold” rating on shares of Colgate-Palmolive in a research report on Friday. Citigroup raised their price target on shares of Colgate-Palmolive from $103.00 to $112.00 and gave the stock a “buy” rating in a research note on Wednesday, July 10th. Finally, BNP Paribas assumed coverage on shares of Colgate-Palmolive in a research note on Monday, June 24th. They issued an “outperform” rating and a $109.00 target price on the stock. Five analysts have rated the stock with a hold rating and fourteen have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $99.42.

Colgate-Palmolive Stock Performance

Colgate-Palmolive stock traded up $0.98 on Monday, reaching $100.37. 2,103,687 shares of the stock were exchanged, compared to its average volume of 4,383,921. The company has a current ratio of 0.42, a quick ratio of 0.28 and a debt-to-equity ratio of 13.21. Colgate-Palmolive has a twelve month low of $67.62 and a twelve month high of $100.90. The firm has a fifty day moving average price of $95.83 and a two-hundred day moving average price of $90.20. The stock has a market cap of $82.35 billion, a PE ratio of 31.80, a PEG ratio of 3.57 and a beta of 0.39.

Colgate-Palmolive (NYSE:CL) last issued its quarterly earnings results on Friday, July 26th. The company reported $0.91 EPS for the quarter, topping the consensus estimate of $0.87 by $0.04. Colgate-Palmolive had a return on equity of 470.19% and a net margin of 14.21%. The company had revenue of $5.06 billion for the quarter, compared to the consensus estimate of $5 billion. During the same period in the previous year, the business posted $0.77 EPS. The company’s revenue for the quarter was up 4.9% on a year-over-year basis. Sell-side analysts anticipate that Colgate-Palmolive will post 3.55 EPS for the current year.

Insider Buying and Selling

In related news, insider John W. Kooyman sold 3,497 shares of the stock in a transaction that occurred on Tuesday, May 7th. The shares were sold at an average price of $93.47, for a total value of $326,864.59. Following the sale, the insider now directly owns 3,181 shares in the company, valued at approximately $297,328.07. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, insider Sally Massey sold 12,226 shares of the stock in a transaction on Thursday, May 9th. The shares were sold at an average price of $94.06, for a total transaction of $1,149,977.56. Following the completion of the sale, the insider now owns 13,924 shares of the company’s stock, valued at $1,309,691.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider John W. Kooyman sold 3,497 shares of the business’s stock in a transaction dated Tuesday, May 7th. The shares were sold at an average price of $93.47, for a total value of $326,864.59. Following the completion of the sale, the insider now owns 3,181 shares in the company, valued at $297,328.07. The disclosure for this sale can be found here. 0.34% of the stock is owned by insiders.

Institutional Investors Weigh In On Colgate-Palmolive

Several institutional investors and hedge funds have recently added to or reduced their stakes in CL. Vanguard Group Inc. raised its position in Colgate-Palmolive by 0.5% during the fourth quarter. Vanguard Group Inc. now owns 79,894,344 shares of the company’s stock worth $6,368,378,000 after acquiring an additional 416,853 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its stake in Colgate-Palmolive by 27.8% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 41,067,130 shares of the company’s stock valued at $3,698,096,000 after purchasing an additional 8,933,912 shares during the last quarter. Norges Bank bought a new position in Colgate-Palmolive during the fourth quarter worth about $731,843,000. GUARDCAP ASSET MANAGEMENT Ltd increased its position in Colgate-Palmolive by 4.1% during the first quarter. GUARDCAP ASSET MANAGEMENT Ltd now owns 6,987,454 shares of the company’s stock worth $629,220,000 after buying an additional 278,150 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its holdings in shares of Colgate-Palmolive by 1.8% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 4,426,430 shares of the company’s stock worth $352,824,000 after acquiring an additional 77,679 shares during the last quarter. 80.41% of the stock is owned by institutional investors.

About Colgate-Palmolive

Colgate-Palmolive Company, together with its subsidiaries, manufactures and sells consumer products in the United States and internationally. It operates through two segments: Oral, Personal and Home Care; and Pet Nutrition. The Oral, Personal and Home Care segment offers toothpaste, toothbrushes, mouthwash, bar and liquid hand soaps, shower gels, shampoos, conditioners, deodorants and antiperspirants, skin health products, dishwashing detergents, fabric conditioners, household cleaners, and other related items.